Cordlife GroupCLIFF 33 PS Ratio is 1.30 as of Jun. 29, 2026, which is 52% below its 10-year median of 2.73. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.20 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Cordlife Group ranks better than 85.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cordlife Group's share price is $0.15048.
Cordlife Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.12. Hence, Cordlife Group's PS Ratio for today is 1.30.
Good Sign:
Cordlife Group Ltd stock PS Ratio (=0.85) is close to 10-year low of 0.81.
The historical rank and industry rank for Cordlife Group's PS Ratio or its related term are showing as below:
CLIFF'
s PS Ratio Range Over the Past 10 Years
Min: 0.81 Med: 2.73 Max: 5.8
Current: 0.85
During the past 13 years, Cordlife Group's highest PS Ratio was 5.80. The lowest was 0.81. And the median was 2.73.
CLIFF's PS Ratio is ranked better than 85.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.81
vs CLIFF: 0.85
Cordlife Group Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Cordlife Group was 36.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -10.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -11.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -3.90% per year.
During the past 13 years, Cordlife Group's highest 3-Year average Revenue per Share Growth Rate was 15.60% per year. The lowest was -21.20% per year. And the median was 0.00% per year.
Back to Basics: PS Ratio
Cordlife Group (OTCPK:CLIFF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cordlife Group PS Ratio Related Terms
Cordlife Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Cordlife Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cordlife Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cordlife Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cordlife Group's Share Price of today is $0.15048. Cordlife Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cordlife Group (CLIFF) has a PS Ratio of 1.30 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cordlife Group and its competitors. This is 52% below median its historical median of 2.73. Over the past decade, Cordlife Group's PS Ratio has ranged from 0.81 to 5.80. According to the industry distribution chart, Cordlife Group ranks #29 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 14.5%.
Is Cordlife Group's PS Ratio too high?
Cordlife Group's current PS Ratio of 1.30 is 52% below median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 5.80. The Medical Diagnostics & Research industry median PS Ratio is 2.81. Cordlife Group's value of 1.30 is 53.7% below this industry median. Based on the distribution chart, Cordlife Group ranks #29 out of 200 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #29 out of 200 companies for PS Ratio. This places Cordlife Group in the top 15% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.81. Cordlife Group's value of 1.30 is 53.7% below this benchmark. Historically, Cordlife Group's own PS Ratio has ranged from 0.81 to 5.80 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 2.81, Cordlife Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.81, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current PS Ratio of 1.30 is 53.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current PS Ratio is 1.30, which is 52% below median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.20, compared to a current price of $0.15 — trading 24.8% below its estimated fair value. The current PS Ratio is 1.30, which is 52% below median its 10-year median of 2.73 and 53.7% below the Medical Diagnostics & Research industry median of 2.81. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current PS Ratio is 1.30 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of $0.15 is trading 24.8% below its estimated GF Value™ of $0.20.
GuruFocus considers Cordlife Group to be Modestly Undervalued.
Key valuation signals for CLIFF:
PS Ratio: 1.30 (52% below median its 10-year median of 2.73)
GF Value™: $0.20 vs. price of $0.15 (24.8% below fair value)
Industry Position: 53.7% below the Medical Diagnostics & Research median (#29 of 200)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
